Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Online ISSN 1827-1898
Tursi A. 1, Elisei W. 2, Giorgetti G. 3, Picchio M. 4, Brandimarte G. 5
1 Gastroenterology Service, ASL BAT, Andria, Barletta-Andria-Trani, Italy;
2 Division of Gastroenterology, ASL Roma H, Albano Laziale, Rome, Italy;
3 Digestive Endoscopy and Nutrition Unit, “S. Eugenio” Hospital, Rome, Italy;
4 Division of General Surgery, “P. Colombo” Hospital ASL RMH, Velletri, Rome, Italy;
5 Division of Gastroenterology, “Cristo Re” Hospital, Rome, Italy
Aim: The aim of the present study was to assess the efficacy of the standard triple therapy containing PPI plus amoxycillin and clarithromycin in curing Helicobacter pylori (H. pylori) infection during a long-term period.
Methods: A retrospective analysis was conducted on 1497 consecutive dyspeptic patients with proven H. pylori infection and enrolled from 1996 to 2006. Patients received a standard triple therapy with proton pump inhibitor (PPI) plus amoxicillin 1 g and clarithromycin 500 mg for 7 days (all twice daily) plus PPI every day for further 4 weeks in case of active peptic ulcer or severe gastritis detected at endoscopy. One month after conclusion of therapy, endoscopy was performed in those patients for whom the examinations were clinically relevant. The remaining patients were checked by ¹³C-urea breath test.
Results: The overall H. pylori eradication rate was 70.41% (on intention-to-treat analysis). However, it decreased significantly during the observation period, ranging from 90% (95% CI 87.14% to 93.91%) in 1996 to 51.11% (95% CI 48.14% to 55.91%) in 2006 (on i-t-t analysis) (P=0.001). No difference in eradicating the was found infection between Puglia and Lazio (1996: P=0.39; 2006: P=0.64).
Conclusion: Standard triple therapy does not appear anymore a valid therapeutic strategy for the management of H. pylori infection in clinical practice.